Drugs / Recombivax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00142753 | Aug 2005 → Nov 2007 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00107042 Comparator | Feb 2004 → Jul 2008 | hepatitis B virus infection | University of North Carolina, Chapel Hill | Completed | Missed primary |
| Phase 4 | NCT02429583 Comparator | May 2015 → Nov 2018 | hepatitis C virus infection | Rockefeller University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombivax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00107042 ↗ |
| Modality | Vaccine | “Recombivax HBV vaccine” NCT02429583 ↗ |